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A Comparative Study of the ReCell® Device and 
Autologous Split-Thickness Meshed Skin Graft in the 
Treatment of Acute Burn Injuries
James Hill Holmes IV, MD*, Joseph A.Molnar, MD, PhD*, Jeffrey E. Carter, MD†,  
James Hwang, MD‡, Bruce A. Cairns, MD||, Booker T. King, MD$, David J. Smith, MD¶,  
C. Wayne Cruse, MD¶, Kevin N. Foster, MD**, Michael D. Peck, MD**, Rajiv Sood, MD††,  
Michael J. Feldman, MD‡‡, Marion H. Jordan, MD||||, David W. Mozingo, MD$$,  
David G. Greenhalgh, MD¶¶, Tina L. Palmieri, MD¶¶, John A. Griswold, MD***,  
Sharmila Dissanaike, MD*** and William L. Hickerson, MD†††
Early excision and autografting are standard care for deeper burns. However, donor sites are a source of significant 
morbidity. To address this, the ReCell® Autologous Cell Harvesting Device (ReCell) was designed for use at the 
point-of-care to prepare a noncultured, autologous skin cell suspension (ASCS) capable of epidermal regeneration 
using minimal donor skin. A prospective study was conducted to evaluate the clinical performance of ReCell vs 
meshed split-thickness skin grafts (STSG, Control) for the treatment of deep partial-thickness burns. Effectiveness 
measures were assessed to 1 year for both ASCS and Control treatment sites and donor sites, including the incidence 
of healing, scarring, and pain. At 4 weeks, 98% of the ASCS-treated sites were healed compared with 100% of 
the Controls. Pain and assessments of scarring at the treatment sites were reported to be similar between groups. 
Significant differences were observed between ReCell and Control donor sites. The mean ReCell donor area was 
approximately 40 times smaller than that of the Control (P < .0001), and after 1 week, significantly more ReCell 
donor sites were healed than Controls (P = .04). Over the first 16 weeks, patients reported significantly less pain at 
the ReCell donor sites compared with Controls (P ≤ .05 at each time point). Long-term patients reported higher 
satisfaction with ReCell donor site outcomes compared with the Controls. This study provides evidence that the 
treatment of deep partial-thickness burns with ASCS results in comparable healing, with significantly reduced 
donor site size and pain and improved appearance relative to STSG. (J Burn Care Res 2018;39:694–702)
Each year, nearly 500,000 Americans suffer from acute thermal 
burn injuries requiring medical treatment, resulting in approxi-
mately 40,000 hospitalizations and 3400 deaths.1–3 Burn treat-
ment is dictated by the depth and extent of the injury, with deeper 
and more extensive injuries requiring early excision and timely 
treatment with autologous split-thickness skin grafts (STSG) 
to achieve definitive closure and optimize clinical outcomes. 
Although the use of STSG is considered standard treatment, 
grafting is associated with significant pain, pruritus, infection, 
dyschromia, dyspigmentation, delayed healing, and hypertrophic 
scarring.4,5 Furthermore, in large TBSA injuries, donor site avail-
ability is a limitation for rapid wound closure using traditional 
skin grafting techniques.
The clinical benefits of earlier intervention for burn wounds 
are well recognized and include increased survival, reduced hos-
pital length of stay, decreased hypertrophic scarring, decreased 
pain duration, and reduced infection-related complications.6–11 
The realization that a treatment in which minimal split-thick-
ness donor skin could be used to achieve definitive closure for 
burn wounds in a clinically advantageous time frame led to the 
investigation of strategies to harness the healing potential of the 
patient’s own skin.
The ReCell® Autologous Skin Cell Harvesting Device 
(ReCell, Avita Medical, Valencia, CA, USA) was designed for 
point-of-care processing of a small split-thickness skin sam-
ple to produce an autologous skin cell suspension (ASCS). 
Using minimal donor skin with an effective treatment area 
expansion ratio of up to 80:1, the ASCS induces rapid epider-
mal regeneration and re-epithelialization. The ReCell device 
consists of a stand-alone, battery operated unit, a proprietary 
enzyme solution, buffer solution, sterile surgical instruments, 
and spray applicators to be used at the point-of-care, with no 
culturing processes involved in the procedure.
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Preclinical data demonstrate that ASCS contains a mixed 
population of skin cells found at the dermoepidermal junction 
of predominantly keratinocyte, fibroblast, and melanocyte phe-
notypes.12 ReCell-generated ASCS has been used to treat a wide 
variety of wound conditions such as burns,13,14 STSG donor 
sites,15 chronic wounds,16,17 hypopigmented scars,18 vitiligo,19,20 
and large congenital melanotic nevus.21 A randomized study 
conducted by Gravante et al demonstrated that deep partial-
thickness burns treated with ASCS produced using the ReCell 
device showed similar results to standard skin grafting, with the 
use of significantly less donor skin. Additionally, subjects treated 
with ASCS reported experiencing significantly less pain than 
patients treated with meshed STSG.13
In burn wounds, the ReCell device is intended to gener-
ate ASCS that retains the known performance attributes of 
a STSG, while minimizing donor site morbidity. The aims of 
this study were to demonstrate similar definitive wound clo-
sure results using ASCS when compared with STSG and dem-
onstrate improved donor site healing with the ReCell device.
MATERIALS AND METHODS
Study Design
This was a multicenter, prospective, within-patient con-
trolled, randomized clinical trial conducted under a U.S. 
Food and Drug Administration (FDA) Investigational Device 
Exemption (NCT01138917). For each patient, two similar 
areas within a burn injury were treated according to random 
assignment, resulting in a control wound treated with a 2:1 
meshed STSG and a ReCell wound treated with ASCS. Donor 
skin for each treatment was harvested from separate but simi-
lar uninjured areas. All study wounds were photographically 
documented throughout the 52-week trial. Before study ini-
tiation, the protocol was approved by the U.S. FDA, the U.S. 
Army Medical Research and Materiel Command Human 
Research Protection Office (USAMRMC HRPO), and 
Institutional Review Boards (IRBs) at each individual site.
Patient Selection
Patients ranging in age from 18 to 65 years were eligible 
for study enrollment if they presented with an acute, deep 
partial-thickness thermal burn from 1% to 20% TBSA that 
required autografting for definitive closure. A minimum 
burn injury treatment area of 200 to 640 cm2 was required, 
allowing for treatment of two separate or contiguous 100 
to 320 cm2 areas. Exclusion criteria for the study included 
the following: burn injuries caused by chemicals, electricity, 
and/or radioactive substances; burn injuries <1% or >20% 
TBSA; treatment areas involving the head, face, neck, hands, 
feet, genitalia, or over joints; presence of pre-existing local or 
systemic infections; antibiotic treatment for >48 hours before 
autografting for other than prophylactic reasons; hypersensi-
tivity to trypsin; a pre-existing chronic condition that in the 
opinion of the investigator might interfere with wound heal-
ing (eg, malignancy, diabetes, or autoimmune disease); ina-
bility to follow the protocol; medications that could interfere 
with wound healing (ie, corticosteroids); other concurrent 
conditions that in the opinion of the investigator might 
compromise patient safety or study objectives; and pregnant 
or breast-feeding women or women who wished to become 
pregnant during the length of study participation.
Randomization
Within-subject allocation of treatments to selected burn 
wounds was performed at random, using a predetermined 
random assignment of treatments. Following excision and 
confirmation of deep partial-thickness depth, and before ran-
domization, the surgeon marked each area as site “A” or site 
“B.” Wound marking was performed using a sterile marker, 
allowing easy identification of the proposed treatment sites. 
An envelope was opened indicating treatment allocation.
Donor Skin Harvesting
For the Control wound donor site, an autograft was harvested 
from a preselected, noninjured skin site according to standard 
of care (SOC), typically at a thickness of 0.008 to 0.010” but 
no less than 0.006”. For the ReCell wound, a thin split-thick-
ness skin sample was harvested at a second donor site discrete 
from the Control wound donor site such that the two wounds 
could be dressed and assessed in isolation. The ReCell wound 
donor site was harvested at a depth of 0.006 to 0.008” with 
the average size of 4.7 cm2. Before processing donor skin with 
the ReCell device, the skin was trimmed down to no greater 
than 4 cm2 (average 3.9 cm2) so that it would cover up to 
320 cm2 or up to 1:80 expansion ratio.
Burn Site Preparation and Treatment
The treatment sites were excised to remove all nonviable 
tissue, and hemostasis was achieved per SOC. The surgeon 
verified that the wound was deep partial-thickness and con-
tained viable dermis throughout the wound base.
ASCS Treatment
Treatment using the ReCell device was performed in accord-
ance with the manufacturer’s instructions. Briefly, the 
split-thickness skin sample was transferred to the warmed pro-
prietary enzyme solution for a period of 15 to 20 minutes 
to promote breakdown of cell-cell and cell-matrix adhesions, 
including those at the dermoepidermal junction. The skin 
sample was then removed from the enzyme, placed on the 
sterile tray of the device, and tested to determine whether the 
epidermis could be freely separated from the dermal tissue. 
When the tissue layers could be freely separated, the skin was 
rinsed in buffer solution and returned to the sterile tray of the 
device, dermal side down. Both the dermal and epidermal lay-
ers were vigorously scraped with a scalpel blade to completely 
disaggregate the skin sample. Following complete disaggre-
gation, the cells were suspended in a buffer solution, filtered, 
drawn into the provided application syringe, and applied over 
the area randomized to receive ASCS treatment.
Meshed STSG Treatment
The harvested STSG was meshed using a skin meshing sys-
tem of choice at a ratio of 2:1. The prepared 2:1 meshed 
STSG was maintained in saline moistened gauze until place-
ment on the prepared wound bed. The autograft was secured 
in place using sutures or staples at the surgeon’s discretion.
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Postoperative Care
After applying the ASCS and the 2:1 meshed autograft, 
both treatment sites were covered with a nonadherent, 
low-absorbent, small pore dressing (Telfa™ Clear Wound 
Dressing, Covidien, Minneapolis, MN). A secondary dress-
ing of Xeroform™ Petrolatum Gauze Dressing (Covidien, 
Minneapolis, MN) was placed over the Telfa Clear primary 
dressing. Additional padding of gauze and a crepe bandage 
were used at the surgeon’s discretion for exudate and protec-
tion. The Telfa Clear primary dressing remained in place for a 
minimum of 6 to 8 days and was not manipulated until the first 
postoperative study visit unless medically necessary. Secondary 
dressings were replaced as needed. Telfa Clear was also used 
as the primary dressing for donor sites, with secondary dress-
ing selection at the discretion of the surgeon. Most frequently, 
Xeroform was used as a secondary dressing for donor sites.
Study Endpoints
Primary effectiveness endpoints were 1) the incidence of 
wound closure (≥95% re-epithelialization) of the treated 
sites at 4 weeks and 2) the incidence of complete donor site 
healing at 1 week (100% re-epithelialization), as determined 
by the surgeon. Percent re-epithelialization of the treatment 
sites was assessed using standardized planimetry/tracing 
procedures. The tracings were uploaded to a central reading 
facility (Canfield Scientific, Parsippany, NJ) for calculation of 
percent re-epithelialization.
Secondary endpoints included pain, visual appearance, and 
scarring. Pain and visual appearance were assessed using visual 
analog scales (VAS-style ratings, 0–100). For both the treat-
ment and donor sites, pain was assessed at weeks 1, 2, 3, 4, 8, 
and 16, and visual appearance was assessed at weeks 16, 24, 
and 52. Investigators used the Vancouver Scar Scale (VSS) to 
evaluate scarring at weeks 16, 24, and 52 for both the treat-
ment and donor sites.
Safety Analyses
All adverse events were summarized and tabulated by treat-
ment, system organ class, and preferred term. Adverse events 
were also evaluated by severity and if they were device-related 
Figure 1. One hundred one consenting subjects meeting inclusion and exclusion criteria were enrolled into the study. Eligible burn injury sites 
were randomized to receive ReCell or Control (2:1 meshed skin graft) treatment and followed over a 52-week period (intention to treat [ITT] 
population). Of these subjects, 87 were evaluated within the per protocol (PP) population analysis and 83 were part of the modified per protocol 
(MPP) population analysis.
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adverse events. Additionally, descriptive statistics were provided 
for the following safety variables including infection at recipient 
sites, infection at donor sites, and graft loss at recipient site.
Statistical Methods
The study was designed to investigate the clinical perfor-
mance of ASCS relative to Control STSG, for the treatment 
of deep partial-thickness burn injuries. Coprimary effective-
ness objectives were to test noninferiority of the incidence of 
ASCS-treated site wound closure at 4 weeks when compared 
with that of the Control, and the superiority of the incidence 
of ReCell donor site healing at 1 week when compared with 
that of the Control.
For the null hypothesis to be rejected and noninferiority 
to be established, the lower limit of the observed one-sided 
97.5% confidence interval was expected to exceed −0.100 (a 
prespecified 10% noninferiority margin) with 81% power when 
the expected difference (πT − πS, Δ1) is 0.000, the proportion 
discordant (η = π10 – π01) is 0.100, and the proportion of 
Table 1. Subject demographics and burn injury 
characteristics
Age (y) 39.5 ± 13.1 (Mean ± Stdev)
18.2–63.5 (Range)
Sex 84.2% Male
15.8 % Female
Race/Ethnicity
58.4% White
19.8% Black
18.8% Hispanic
Etiology
77.2% Fire/flames
14.9% Hot water/steam
6.9% Excessive heat
1.0% Fire/flames/excessive 
heat
Treatment postburn injury (d)
7.1 ± 3.0 (Mean ± Stdev)
2–19 (Range)
TBSA (%) 10.0 ± 4.5 (Mean ± Stdev)
3–20 (Range)
Figure 2. Autograft Sparing Analysis. (A) Treatment and donor site wound areas. The mean size of treatment sites was 168.2 ± 68.0 cm2 (ASCS/
ReCell) and 165.0 ± 66.5 cm2 (Control). Mean size of donor sites was 4.7 ± 3.2 cm2 (ASCS/ReCell) and 194.1 ± 158.5 cm2 (Control). * indicates 
a statistical difference with P < .0001. (B) Clinical case example of donor site harvest areas for ASCS/ReCell skin sample and Control split-thickness 
skin graft.
 Journal of Burn Care & Research
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both yes (π11) is 0.750 for a population of 90 subjects. Results 
are based on 1000 simulations using the Newcombe–Wilson 
score method to construct the confidence interval.22
The noninferiority margin of 10% was determined based 
on input from experienced burn surgeons and considered 
two factors: 1) it is normal for there to be minor variation 
in the rate of healing even for the same patient and 2) the 
clinical benefit that is realized at the donor site (ie, a smaller, 
faster-healing donor site) provides balance for acceptance of 
a 10% noninferiority margin for recipient site healing.
In the comparison of the coprimary endpoint of superiority 
of donor site wound healing between the ReCell donor site 
and the STSG donor site, it was assumed that at least 95% of 
the ReCell donor sites would be healed at 1 week, whereas 
40% of the STSG donor sites would remain unhealed. For 
these assumptions, a sample size of 42 pairs will have 95% 
power to detect a difference in proportions of 0.350 when the 
proportion of discordant pairs is expected to be 0.500 and the 
method of analysis is a McNemar’s test of equality of paired 
proportions with a 0.050 two-sided significance level.
Thus, a recruitment target was established aiming to yield 
90 evaluable subjects such that the noninferiority analysis is 
sufficiently powered.
Populations for Analysis
Study populations (Figure 1) were defined as follows: 
1) Intent-to-treat population (ITT): all randomized subjects 
(n = 101) which was used for demographics, evaluation of 
safety, superiority of donor site healing, and scar ratings; 
2) Per-protocol (PP) population(n = 87): ITT subjects who 
receive both study treatments in accordance with the ran-
domization, completed 4 weeks of follow-up and had no 
major protocol deviations up to 16 weeks which was used 
for evaluation of patient self-report of pain and appearance 
(of both treatment and donor areas); and 3) Modified Per-
protocol (MPP) population (n = 83): PP subjects who did 
not undergo concomitant therapy known to impair wound 
healing (ie, use of topical silver sulfadiazine [SSD]). The ITT 
and PP populations were prospectively defined. The MPP 
population was defined post hoc to resolve concern that the 
PP population included subjects with results confounded by 
the use of a cytotoxic agent concomitant with the ASCS. At 
the initiation of the study, SSD use was not contraindicated, 
as its use was not anticipated; therefore, it was determined 
that excluding these patients from the PP population was not 
appropriate within the context of an FDA clinical trial.
The statistical analysis of the data obtained from the 
study was conducted by an independent third-party (BioStat 
International, Tampa, FL) using SAS Version 9.3. Continuous 
variables were summarized using descriptive statistics, specif-
ically the mean, median, standard deviation, minimum, and 
maximum. Categorical variables were summarized by fre-
quencies and percentages.
Figure 3. Incidence of definitive closure at treatment site. The pri-
mary effectiveness analyses to evaluate noninferiority of the incidence 
of treatment site wound closure with autologous skin cell suspension 
(ASCS) compared with Control treatment at week 4 was performed 
on the MPP population. The proportion of subjects with treatment 
site wound healing at week 4 was 97.6% for ASCS and 100% for 
Control with a −2.4% difference in proportions and a 95% CI: −8.4%, 
2.3%. As the lower bound of the 95% CI is greater than the predefined 
−10% NI margin, noninferiority was established.
Figure 4. Pain and visual appearance assessments at treatment site. 
(A) Pain was assessed at weeks 1, 2, 3, 4, 8, and 16 by the VAS Pain 
Scale. No difference in pain was reported between the autologous 
skin cell suspension (ASCS) and Control treatment sites. Visual 
appearance of the treatment site (B) and scarring at the treatment site 
(C) was assessed at weeks 16, 24, and 52. (B) No difference in visual 
appearance (VAS Appearance Scale) was reported between the ASCS 
and Control treatment sites. (C) No difference in scarring (Vancouver 
Scar Scale) was reported between the ASCS and Control treatment 
sites.
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RESULTS
Between May 2010 and August 2014, 133 patients were 
assessed for eligibility across 12 burn centers within the 
United States, and 101 patients were enrolled in the study. 
The mean patient age was 39.5 ± 13.1 years, and 84% 
of the patients were male, whereas the majority of burns 
(77%) were due to fire/flame-related injuries (Table 1). 
Subjects received treatment, on average, 7.1 ± 3.0 days 
following their burn injury, allowing time for confirmation 
that the depth of injury was such that autografting was 
medically indicated (Table 1).
Of the 101 patients enrolled (ITT), 87 subjects completed 
the 52-week follow-up without major protocol deviations 
(PP). The analysis population for incidence of definitive clo-
sure of the treatment sites (MPP) consisted of 83 subjects, 
with four subjects being excluded from the PP population 
who had SSD applied at the ASCS-treated sites following 
ASCS application (Figure 1).
The two treatment areas were comparable with respect to 
anatomic location and size, with the ASCS treatment area aver-
aging 168 cm2 and control treatment area 165 cm2 (Figure 2). 
The average area of the donor sites for ASCS was approxi-
mately 40 times smaller than the average area of the donor sites 
for the control treatment (4.7 ± 3.2 cm2 vs 194.1 ± 158.5 cm2, 
respectively; P < .0001; Figure 2), translating to a donor site 
size reduction of 97.5%. The average amount of donor tissue 
required to prepare ASCS was 3.9 ± 0.3 cm2 as it was necessary 
to trim the donor tissue to obtain a final size of up to 4 cm2 (to 
cover an area up to 320 cm2).
Treatment Sites
Both treatments were clinically effective in healing >97% of the 
treated burns by week 4. The incidence of definitive closure, 
as defined as ≥95% re-epithelialization, was 97.6% (81/83) for 
the ReCell-generated ASCS treated site and 100% (83/83) 
for the control STSG–treated site (Figure 3). The difference 
in proportions between the two groups was −2.4% (95% CI: 
−8.4% to 2.3%). Therefore, the healing of ASCS-treated sites 
was statistically comparable to those sites treated with a 2:1 
meshed STSG, thus substantiating the noninferiority primary 
effectiveness endpoint.
Additionally, subject-reported pain at the treatment site 
during the first 16 weeks was not significantly different 
between the ASCS and control sites (Figure 4A). Similarly, 
long-term results at 16, 24, and 52 weeks showed no differ-
ence in subject satisfaction with appearance (Figure 4B) or in 
scarring (Figure 4C) at the ASCS-treated sites compared with 
the control sites. Following treatment site healing, no late-
term wound breakdown was reported.
Donor Sites
At 1 week, the incidence of donor site healing in the ReCell 
group was shown to be superior to the control group (21.8% 
vs 10.0%; P = .04, Figure 5), thus validating the superiority 
Figure 5. Incidence of definitive closure at donor site. Wound heal-
ing of the donor sites taken for the ReCell treatment and the Control 
treatment was assessed at the 1- and 2-week visits. Significantly more 
donor sites taken for ReCell were healed when compared with the 
Control donor site wounds at weeks 1 and 2 (Week 1: * indicates 
P < .05; Week 2: ** indicates P < .001).
Figure 6. Pain and visual appearance assessments at donor site. (A) 
Pain was assessed at weeks 1, 2, 3, 4, 8, and 16 by the VAS Pain Scale. 
Subjects reported statistically significantly less pain at the ReCell 
donor site than the Control donor site through the 8-week visit (* 
indicates P ≤ .005 at each interval). Visual appearance of the donor 
site (B) and scarring at the donor site (C) was assessed at weeks 16, 24, 
and 52. Patients expressed significantly greater satisfaction with the 
visual appearance (VAS Appearance Scale) of the ReCell donor sites 
compared with the Control donor sites at the weeks 16, 24, and 52 
(* indicates P ≤ .005 at each interval). Reduced scarring (Vancouver 
Scar Scale) was reported at the ReCell donor sites compared with the 
Control donor sites (* indicates P ≤ .005 at each interval).
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primary effectiveness endpoint. At week 2, the incidence of 
donor site healing in the ReCell group was also statistically 
significant in favor of the ReCell donor site (90.0% vs 67.3%; 
P < .001) with an odds ratio of 4.3. Additionally, this superi-
ority persisted and subjects reported a statistically significant, 
and clinically meaningful, reduction in pain at the ReCell 
donor site compared with the Control donor site through the 
week-8 visit (P ≤ .005 at each interval, Figure 6A). Long-term 
assessments at weeks 16, 24, and 52 showed that subjects 
expressed greater satisfaction with the visual appearance of 
the ReCell donor sites compared with the Control donor sites 
(P ≤ .005 at each interval, Figure 6B). Reduced scarring was 
also reported at the ReCell donor sites compared with the 
Control donor sites (P ≤ .005 for each time point, Figure 6C).
Safety
All safety analyses were conducted on the ITT population. The 
majority of adverse events (AEs), including treatment and donor 
sites, were mild in nature (83.3% and 91.3% for ASCS-treated 
sites and Control-treated sites, respectively; Table 2), and there 
were no subject deaths reported (Table 2). The greater incidence 
of AEs noted at the ASCS-treated sites is primarily attributed to 
the application of SSD following ASCS application and reinjury 
at the recipient site due to lack of protective dressings/garments 
following initial re-epithelialization. There were no events of late 
wound breakdown at either the ASCS- or Control-treated sites. 
Overall, AEs reported for ASCS-treated sites were typical for the 
type of injury sustained by subjects with burn wounds requiring 
skin grafting procedures.
Five device-related AEs were reported as follows: two mild 
skin graft failures and three hypertrophic scarring (two mild 
and one moderate). However, for 2 of 3 subjects, hypertrophic 
scarring was reported at the Control site and other nonstudy 
wounds as well. Therefore, the relatedness of the scarring to 
the study device is questionable. Overall, two subjects under-
went subsequent intervention for graft loss at the ReCell site 
(one regrafting procedure and one debridement with redress-
ing). In both cases, the wounds were healed at 4 weeks and 
remained healed.
For the ReCell and Control donor sites, there were no dif-
ferences in the incidence of AEs (4.0% vs 6.9%, respectively, 
P = .25). At the treatment sites, a greater number of total AEs 
occurred with the ReCell treatment than the Control treat-
ment (35.6% vs 21.8%, respectively, P = .0013).
Representative Case Example
A 62-year-old white male sustained an 8.5% TBSA flame burn 
inclusive of an injury to the left forearm (Figure 7). The burn 
was excised and divided into two sites (A and B), and these 
sites were randomized. The site assigned to ASCS was (B) 
and measured 185 cm2, whereas the site assigned to Control 
STSG was (A) and measured 121 cm2. A 90.25-cm2 STSG 
was harvested from the left anterior thigh at 0.010” thick, 
meshed 2:1, and applied to site A (control). A 4-cm2 skin sam-
ple was harvested from the medial thigh at 0.007” thick and 
processed using the ReCell device, with ASCS being applied 
to Site B. Telfa Clear was used to cover both of the treated 
sites and donor sites, followed by Xeroform and gauze dress-
ings. One week following intervention, both the ASCS site 
and the control site were healed. At week 52, the color and 
pigment of the ASCS site matched surrounding skin, whereas 
the control site was mildly mismatched in color and pigment. 
The overall VSS for the control site was 2, whereas the ASCS-
treated site was 0.
Table 2. Summary of adverse events
Adverse Events ReCell n* (%) Control n* (%)
ReCell vs Control
P†
No Adverse Events 65 (64.4%) 78 (77.2%) 0.0044
Mild 30 (29.7%) 21 (20.8%)
1.0000
Moderate 5 (5.0%) 1 (1.0%)
Severe 1 (1.0%) 1 (1.0%)
Treatment Site Adverse Events
Total (Any primary system organ class) 36 (35.6%) 22 (21.8%) 0.0013
Total Infections and Infestations 3 (3.0%) 2 (2.0%) 1.0000
Injury, Poisoning, and Procedural Complications 10 (9.9%) 2 (2.0%) 0.0215
Total Skin and Subcutaneous Tissue Disorders 26 (25.7%) 16 (15.8%) 0.0129
Device-Related Adverse Events
Total (Any primary system organ class) 5 (5.0) N.A.
Skin graft failure 2 (2.0) N.A.
—Hypertrophic scar 3 (3.0) N.A.
Donor Site Adverse Events
Total (Any primary system organ class) 3 (4.0) 6 (6.9) 0.2500
Total Infections and Infestations 0 (0.0) 1 (1.0) 0.5000
Injury, Poisoning, and Procedural Complications 0 (0.0) 1 (1.0) —
Total Skin and Subcutaneous Tissue Disorders 3 (3.0) 4 (4.0) 0.5000
*Subjects with multiple occurrences of a preferred term is counted only once for that preferred term.
†P-value obtained using McNemar’s test.
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DISCUSSION
In this study, it was demonstrated that the use of ASCS gener-
ated from the ReCell® Autologous Cell Harvesting Device is 
a safe and effective alternative to conventional meshed auto-
grafting for the treatment of deep partial-thickness burns. It 
was demonstrated that, at 4 weeks, in a patient population 
receiving proper wound care, the incidence of healing was 
comparable between the treatment groups (97.6% for ASCS 
and 100% for Control), with no differences in pain, subject 
satisfaction with appearance, or scarring outcomes.
Additionally, ReCell donor sites demonstrated increased 
healing, decreased pain, improved subject satisfaction with 
appearance, and less scarring. It was demonstrated that the 
requirement for harvesting of donor skin may be 1/80th 
the size of the burn injury area treated when using the 
ReCell device, thus reducing the skin required for cover-
age by 97.5% relative to 2:1 meshed STSG. Furthermore, as 
shown in this study, the use of ReCell additionally decreases 
the donor site depth compared with standard grafting, likely 
contributing to the reduced pain and improved healing 
outcomes.
Using ReCell, the reduction of donor skin requirements 
gives rise to significant clinical benefits, offering surgeons a 
new strategy for the treatment of burn injuries. This is partic-
ularly true for patients having limited donor tissue availability, 
as well as for patients in whom the creation of larger donor 
sites may lead to significant morbidity. Additionally, for inde-
terminate depth injuries where skin grafting is intentionally 
delayed until it is certain that a graft is needed for definitive 
Figure 7. Clinical case. A 62-year-old white male sustained an 8.5% TBSA injury from fire/flames inclusive of an injury to the left forearm. The 
burn wound on the left forearm was excised and divided into two sections (A and B) and these sites were randomized as the autologous skin cell 
suspension (ASCS) or Control wounds. Site A received the control treatment (2:1 meshed STSG) and site B ASCS. Telfa Clear was used to cover 
both treated sites followed by Xeroform and bulky dressings. At 4 weeks, both treatment sites were healed. At 52 weeks, the color and pigment of 
the ASCS treatment site matched surrounding skin, whereas the Control treatment site was mildly mismatched in color and pigment.
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closure, the use of ReCell may be a solution for earlier inter-
vention, as morbidity and complications associated with donor 
sites are reduced.
This study provides definitive evidence for the safe and 
effective use of ReCell in the treatment of deep partial-
thickness burns. As part of the study design to mitigate the 
variability across groups, treatment was limited to an area of 
320 cm2 in burns of 1% to 20% TBSA and excluded appli-
cation to joints, hands, feet, genitalia, and faces. Although 
this study excluded these patients and treatment regions, 
previously published studies using ReCell demonstrate suc-
cessful use in deep partial-thickness injuries for patients with 
varying TBSA and across various anatomic locations.13,23,24 
In addition, ReCell treatment to the donor sites has previ-
ously been shown to significantly improve donor site heal-
ing.15 Therefore, based on the collective data, the authors 
conclude that the results demonstrated in this study may be 
extrapolated for the treatment of all deep-partial thickness 
thermal burns.
Further implications from this study include the impor-
tance of understanding the learning curve clinicians must 
overcome in using innovative cellular products. During this 
study, adverse events occurred that were not attributable to 
the ASCS application but were due to the failure of proper 
after care. As the cellular suspension contains disaggregated 
skin cells, it is critical that the environment is optimized to 
allow for the regeneration and maturation into a robust epi-
dermal layer. Thus, following ASCS application, cytotoxic 
agents must be avoided and dressings and garments should be 
used to protect the newly formed skin.
CONCLUSION
Overall, the study demonstrates that ASCS generated by the 
ReCell device is a viable alternative to STSG for the treat-
ment of deep partial-thickness thermal burns. Definitive 
wound closure of ASCS-treated sites was comparable to 
sites treated with 2:1 meshed autograft. Patients benefitted 
from significantly improved incidences of donor site healing 
and reduced pain and morbidity of the associated smaller 
donor sites. Reducing the amount of donor skin required 
to achieve complete and definitive burn wound closure 
opens the possibility for treating extensive and complex 
burns sooner than the current SOC. These findings have 
potential implications for a paradigm shift in the approach 
used to achieve rapid and permanent closure of burn inju-
ries. Furthermore, achieving definitive closure using less 
skin compared with standard autografting has the potential 
to decrease the number of surgical procedures required to 
achieve wound closure as well as reducing hospital length of 
stay, thus decreasing the overall costs related to the treat-
ment of burn injuries.
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